Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2016

View Archived Issues

Phase III study planned for lurbinectedin in metastatic breast cancer based on phase II results

Exicure reports phase I results for AST-005

Novel TRIM32 gene mutation linked to distal myopathy

FDA accepts IND for Kempharm's KP-415

Bristol-Myers Squibb patents TNF-alpha antagonists

EMA issues positive opinion on Atara Biotherapeutics' CMVpp65-CTL

FDA approves infant-specific dose of Pertzye

Abide Therapeutics discloses monoacylglycerol lipase inhibitors

FDA grants fast track designation to CC-8464 for neuropathic pain associated with iSFN

FDA grants QIDP and fast track designation to Viamet Pharmaceuticals' VT-1161

ChemBridge describes GPR131 agonists

Biocad advances BCD-085 into phase II trials for severe psoriasis

BioNTech develops seprase binding peptides

Takeda Pharmaceutical presents EIT6 inhibitors

Full results from European phase III study of Infacort in pediatric adrenal insufficiency

New mutations in ABCA4 gene may be involved in cone dystrophy

Novel homozygous mutation in CERKL causes autosomal recessive retinitis pigmentosa

Positive phase IIb results for SPN-812 in children with ADHD

Phase II results lead NeuroVive to discontinue development of CicloMulsion for acute kidney injury

FDA approves Protein Sciences' Flublok influenza vaccine

Novel SPEG gene mutation linked to centronuclear myopathy

Aeterna Zentaris and Specialised Therapeutics Asia sign exclusive agreement for Zoptrex

RXi Pharmaceuticals in exclusive option agreement to acquire MirImmune

Paratek Pharmaceuticals signs agreement with USAMRIID for omadacycline research

Prometheus completes validation of PROMETHEUS Anser VDZ test

Prometic Life Sciences will continue enrollment in phase II trial of PBI-4050

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...